EN DE
Watch Dianthus Therapeutics Inc. for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Dianthus Therapeutics Inc. (DNTH) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of Dianthus Therapeutics Inc. stock $42.54, price $88.81, that is 52.1% below the price, quality 23 out of 100. Rating: strongly overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US

DT Dianthus Therapeutics Inc. logo Thin data Nov 11, 2026

Dianthus Therapeutics Inc.

DNTH · US
Very expensive, weak quality

Our calculation puts a fair price 52% below what the stock costs today.

Neutral coverage
Insiders sold $34.1M (6M)
Fair value $42.54 · Strongly overvalued
Quality 23/100
Weak Growth (revenue 3y −31.8 %/yr in USD)
Negative free cash flow
Trails peers (2/6)
Narrow moat 8/100 · thin data
Thin data
Estimate
Watch Dianthus Therapeutics Inc. for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$133.28 $5.76 Fair Value $42.54 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 11, 2026.

How to read this chart

60‑month range $5.76 – $133.28 · fair‑value band $31.91 – $53.18 · the $88.81 price screens above the $42.54 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 11, 2026.

Follow Dianthus Therapeutics in your weekly email

Every Wednesday you see whether Dianthus Therapeutics is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases.

Show moreShow less

Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function.

Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.

Stock analysis

Dianthus Therapeutics Inc. (DNTH) currently trades at $88.81, while our estimate is $42.54, 52% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: $31.91 (bear) to $53.18 (bull), the price of $88.81 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 23/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

Dianthus Therapeutics Inc. reported revenue of $2.0M in FY2025 versus $1.5M in FY2021, a compound +8.4%/yr. Reported net income was −$162M in FY2025.

Key figures

Market cap $5.0B Mid · EPS (TTM) $−4.27 · Return on equity −22.6% · Return on assets (EBIT) −26.0% (5-year average) · Operating margin −4,832% · Revenue (TTM) $2.7M · Revenue growth (YoY) +206% · Free cash flow −$129M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 8 out of 100 (low confidence).

What moves the price

The share trades about 23% below its 52-week high and 150% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −52%, DNTH screens richer than that median.

Fair Value

Bear $31.91 Fair Value $42.54 Bull $53.18
Price $88.81 · Downside -52.1%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 23/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 19
Are margins and returns getting better?
Cashflow 7
Do the profits arrive as real cash?
Financial strength 83
Debt, balance sheet and risk of trouble
Investment 18
Does it invest with discipline instead of growing at any price?
Low Volatility 51
How calm the share price moves, does not count
Price momentum 55
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 83
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, 7 officers or directors sold shares worth $34.1M and none bought.

  • SaleEdward CarrCHIEF ACCOUNTING OFFICER2× since Mar 12, 2026: 63,682 shares, avg. $87.74$5.6MSep 17, 202610b5-1 plan
  • SaleSimrat RandhawaEVP, Head of R&D4× since Nov 13, 2025: 280,022 shares, avg. $53.57$15.0MSep 1, 202610b5-1 plan
  • SaleSimon ReadDirector2× since Aug 10, 2026: 5,555 shares, avg. $113.55$630,786Aug 19, 202610b5-1 plan
  • SaleAdam M VenessSVP, General Counsel and Sec.2× since Jun 17, 2026: 50,000 shares, avg. $92.66$4.6MAug 10, 202610b5-1 plan
  • SaleAnne McGeorgeDirector7,750 shares at $109.01$844,822Aug 10, 202610b5-1 plan
  • SaleMarino GarciaCEO AND PRESIDENT, Director2× since Mar 12, 2026: 288,918 shares, avg. $96.78$28.0MAug 7, 202610b5-1 plan
  • SaleRyan SavitzEVP, CFO & CBO4× since Dec 4, 2025: 173,840 shares, avg. $82.21$14.3MJul 9, 202610b5-1 plan
  • SalePaula SoteropoulosDirector3× since Mar 24, 2026: 28,792 shares, avg. $78.25$2.3MMay 8, 202610b5-1 plan

Plus 11 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 10, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−67.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−31.8%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−886.6% (2021) → −8,739.3% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

DNTH screens overvalued: fair value 52% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Recent news

News mood ⓘNews mood, the average tone of recent news (81 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation. Neutral
Recent news coverage is roughly neutral, about typical for how stocks are covered.

Compare Dianthus Therapeutics Inc. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 850 stocks

Beats the industry median on 1/5 measures
Overall it trails its industry peers.
Valuation
Quality Score 23 · Bottom 25%
Fair Value upside −52.1% · Bottom 25%
Profitability
Return on assets −30.6% · Below median
Growth and dividend
Revenue growth (quarter YoY) 205.6% · Top 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 10.08× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)100 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)0 · sector 96
DIVIDEND (yield)0 · sector 20

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $916.06 $1,275 +39% vs DNTH
Samsung Biologics Co 207940 1,468,000 KRW 1,661,000 KRW +13% vs DNTH
Vertex Pharmaceuticals Incorporated VRTX $547.89 $601.80 +10% vs DNTH
Genmab A/S GMAB kr 3,581 kr 3,880 +8% vs DNTH
argenx SE ARGX $971.55 $908.40 −7% vs DNTH
CSL Limited CSL A$201.68 A$181.40 −10% vs DNTH
Moderna, Inc MRNA $250.83 $158.70 −37% vs DNTH
BeOne Medicines AG 6160 HK$252.20 HK$152.80 −39% vs DNTH
Celltrion, Inc 068270 203,000 KRW 74,945 KRW −63% vs DNTH
Royalty Pharma plc RPRX $69.45 $19.01 −73% vs DNTH

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Dianthus Therapeutics Inc.: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Dianthus Therapeutics Inc. Fair Value". https://www.fairvalue-calculator.com/stock/DNTH

Frequently asked questions

Is Dianthus Therapeutics Inc. (DNTH) overvalued or undervalued?
As of Nov 11, 2026, our estimate of fair value is $42.54 versus a price of $88.81, about 52% lower (overvalued).
What is the fair value of DNTH?
Our estimate for Dianthus Therapeutics Inc. is $42.54 (as of Nov 11, 2026), built from audited fundamentals. The current price: $88.81.
What is the quality score of DNTH?
Dianthus Therapeutics Inc. has a Quality Score of 23/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Dianthus Therapeutics Inc. (DNTH)?
Our calculated price target is the estimate of $42.54 (as of Nov 11, 2026). Cautious scenario $31.91, optimistic scenario $53.18. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Dianthus Therapeutics Inc. stock forecast for 2026?
Our estimate puts fair value at $42.54, about 52% lower versus a price of $88.81 (overvalued). Cautious scenario $31.91, optimistic scenario $53.18. The calculation is refreshed regularly with new filings.
What is the revenue of Dianthus Therapeutics Inc. (DNTH)?
Dianthus Therapeutics Inc. reported trailing-twelve-month revenue of about $2.7M (latest available figure, as of Nov 11, 2026).
What is the intrinsic value of Dianthus Therapeutics Inc. (DNTH)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Dianthus Therapeutics Inc. it is $42.54 per share (as of Nov 11, 2026), against a price of $88.81.
Is Dianthus Therapeutics Inc. stock overvalued or undervalued in 2026?
As of Nov 11, 2026, DNTH trades above its calculated fair value: price $88.81, fair value $42.54, a gap of about −52% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of DNTH?
No. The price is what the market pays today ($88.81); the fair value is what the company's own numbers justify ($42.54). For Dianthus Therapeutics Inc. the two are $46.27 per share apart. That gap is exactly why we show both numbers side by side.
How much is Dianthus Therapeutics Inc. worth?
The market values Dianthus Therapeutics Inc. at about $5.0B (market capitalisation, as of Nov 11, 2026). Per share that is $88.81; our models calculate a fair value of $42.54 per share.
What do the bullish and bearish scenarios say about DNTH?
Our models span a range for Dianthus Therapeutics Inc.: cautious scenario $31.91, base $42.54, optimistic $53.18 per share (as of Nov 11, 2026, price $88.81). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Dianthus Therapeutics Inc. (DNTH)?
Balance-sheet figures for Dianthus Therapeutics Inc. (as of Nov 11, 2026): return on equity −22.6%. They feed the Quality Score of 23/100, which measures business quality independently of the share price.
How far is DNTH from its 52-week high?
Dianthus Therapeutics Inc. trades at $88.81, about 23% below its 52-week high of $115.96 and 150% above the low of $35.50 (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of $42.54 is for.
Which stocks are comparable to Dianthus Therapeutics Inc.?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Dianthus Therapeutics Inc. stock attractive at the current price?
The data as of Nov 11, 2026: price $88.81, calculated fair value $42.54 (−52%), Quality Score 23/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. Dianthus Therapeutics Inc. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Dianthus Therapeutics Inc. (DNTH)?
The closing price on Nov 10, 2026 was $88.81. Our estimate is $42.54, about 52% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Dianthus Therapeutics Inc. right now?
The price sits above even our optimistic bull case ($53.18). The favourable scenario is already priced in. Weak quality (23/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of Dianthus Therapeutics Inc.

How large is the market capitalisation of Dianthus Therapeutics Inc. (DNTH)?
The market capitalisation of Dianthus Therapeutics Inc. is $5.0B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Dianthus Therapeutics Inc. (DNTH)?
Earnings per share at Dianthus Therapeutics Inc. are $−4.27. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Dianthus Therapeutics Inc. (DNTH)?
The return on equity (ROE) of Dianthus Therapeutics Inc. is −22.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Dianthus Therapeutics Inc. (DNTH)?
On an EBIT basis the return on assets of Dianthus Therapeutics Inc. is −26.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Dianthus Therapeutics Inc. (DNTH)?
The operating margin of Dianthus Therapeutics Inc. is −4,832% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Dianthus Therapeutics Inc. (DNTH)?
Revenue at Dianthus Therapeutics Inc. is growing +206% versus a year earlier (3y avg −31.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Dianthus Therapeutics Inc. (DNTH) generate?
The free cash flow of Dianthus Therapeutics Inc. is −$129M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Dianthus Therapeutics Inc. (DNTH) hold?
Dianthus Therapeutics Inc. holds more cash than debt, $49.7M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Dianthus Therapeutics Inc. in the live analysis

One click puts Dianthus Therapeutics Inc. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.